Pharmaceutical Medicine

Scope & Guideline

Elevating standards in pharmacology and therapeutic practices.

Introduction

Delve into the academic richness of Pharmaceutical Medicine with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1178-2595
PublisherSPRINGER INT PUBL AG
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2000 to 2001, from 2008 to 2024
AbbreviationPHARM MED / Pharm. Med.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressGEWERBESTRASSE 11, CHAM CH-6330, SWITZERLAND

Aims and Scopes

The journal 'Pharmaceutical Medicine' focuses on advancing knowledge and practices in the pharmaceutical industry, particularly in the areas of drug development, regulatory affairs, and medical affairs. Its core aims and scopes include:
  1. Pharmaceutical Research and Development:
    Exploration of methodologies and innovations in drug discovery, development, and approval processes, with a focus on enhancing efficiency and effectiveness.
  2. Regulatory Affairs and Compliance:
    Analysis of regulatory frameworks, compliance challenges, and evolving guidelines affecting drug approval and market access across various regions.
  3. Medical Affairs and Education:
    Investigation into the role of medical affairs in the pharmaceutical industry, including education strategies for healthcare providers and engagement with patients.
  4. Pharmacovigilance and Drug Safety:
    Emphasis on monitoring drug safety post-marketing, signal detection, and implementation of risk minimization measures to ensure patient safety.
  5. Patient-Centric Approaches:
    Incorporation of patient perspectives in drug development and clinical trials, focusing on adherence, preferences, and outcomes.
  6. Emerging Technologies in Pharmaceuticals:
    Assessment of the impact of digital technologies, artificial intelligence, and real-world evidence on pharmaceutical practices and healthcare delivery.
Recent publications in 'Pharmaceutical Medicine' have highlighted several emerging themes that reflect the current trends and priorities in the pharmaceutical landscape. These areas are gaining attention and are likely to shape future research directions. The following points outline these trending and emerging scopes:
  1. Artificial Intelligence and Machine Learning Applications:
    The increasing integration of AI and machine learning in drug development and pharmacovigilance indicates a significant trend towards leveraging technology to enhance efficiency and data analysis.
  2. Patient-Centric Drug Development:
    A growing emphasis on patient engagement and the incorporation of patient preferences in clinical trial design and drug development processes showcases a shift towards more patient-centered approaches.
  3. Real-World Evidence Utilization:
    The use of real-world data to inform decision-making in drug approval and post-marketing assessments is emerging as a critical area of focus, reflecting the industry's need for better understanding of drug effectiveness in diverse populations.
  4. Diversity, Equity, and Inclusion in Clinical Trials:
    Increasing attention to diversity and inclusion within clinical trial populations highlights the industry's commitment to addressing health disparities and ensuring equitable access to treatments.
  5. Decentralized Clinical Trials:
    The rise of decentralized clinical trials, facilitated by technology and remote monitoring, represents a significant shift in how clinical studies are conducted, aiming to improve patient participation and data collection.

Declining or Waning

While 'Pharmaceutical Medicine' has consistently focused on various critical aspects of pharmaceutical science, certain themes have shown a decline in prominence over recent years. These waning scopes may reflect shifting priorities within the field or the maturation of certain topics. The following points summarize these declining themes:
  1. Traditional Clinical Trial Models:
    There is a noticeable decrease in publications focusing on conventional clinical trial methodologies, possibly due to the rise of decentralized trials and adaptive designs.
  2. Single-Use Drug Formulations:
    Research on single-use formulations seems to be declining as the industry shifts towards more comprehensive therapeutic strategies and complex drug delivery systems.
  3. Pharmaceutical Marketing Strategies:
    Discussions around traditional pharmaceutical marketing tactics are less frequent, indicating a shift towards more integrated and value-based approaches to market access.
  4. Regulatory Challenges in Established Markets:
    The focus on regulatory challenges specific to established markets (e.g., EU, USA) is diminishing, possibly as the industry adapts to newer regulatory frameworks and harmonization efforts.
  5. Post-Marketing Studies:
    There appears to be a reduction in studies solely dedicated to post-marketing surveillance of drugs, as new methodologies for real-world evidence gain traction.

Similar Journals

Indian Journal of Pharmaceutical Education and Research

Transforming the landscape of pharmaceutical sciences through research.
Publisher: ASSOC PHARMACEUTICAL TEACHERS INDIAISSN: 0019-5464Frequency: 4 issues/year

Indian Journal of Pharmaceutical Education and Research, published by the Association of Pharmaceutical Teachers of India, is a pivotal platform for scholarly discussion in the field of pharmacology, toxicology, and pharmaceutics. ISSN 0019-5464, this esteemed journal aims to foster the exchange of innovative research, clinical advancements, and educational practices within the pharmaceutical sciences community. As a Q3-ranked journal in its category as of 2023, it reflects a commitment to upholding the standards of academic excellence and contributes significantly to the ongoing development of pharmaceutical education. The journal is a valuable resource for researchers, professionals, and students, with content spanning various key areas including drug formulation, safety, and the latest trends in pharmaceutical education. By providing open access to its research and reviews, the journal ensures that vital information is disseminated widely, promoting collaboration and learning among stakeholders in the pharmaceutical sector. Based in Bangalore, India, the journal has been instrumental in highlighting regional research while fostering a global dialogue in pharmaceutical sciences. As it continues its journey from 2008 to 2024, it remains dedicated to impacting the field through rigorous peer-reviewed content and engaging with contemporary challenges in healthcare and education.

PHARMAZIE

Illuminating the future of drug development and safety.
Publisher: AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBHISSN: 0031-7144Frequency: 12 issues/year

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

ACTA PHARMACEUTICA

Unlocking the potential of pharmaceutical research for all.
Publisher: SCIENDOISSN: 1330-0075Frequency: 4 issues/year

ACTA PHARMACEUTICA is a distinguished open-access journal published by SCIENDO, dedicated to advancing knowledge in the fields of medicine and pharmaceutical sciences. Established in 1992, the journal has made significant contributions to the scholarly community, providing a platform for innovative research and discussion. With a strong presence in both Q2 and Q3 quartiles across various categories including Pharmaceutical Science and Pharmacology, ACTA PHARMACEUTICA ranks favorably, positioning its contributions in the upper tiers of the field. The journal's commitment to open access since 2007 ensures that both practitioners and scholars have immediate access to cutting-edge developments, thereby fostering collaboration and knowledge sharing. With its scope spanning a broad spectrum of pharmaceutical and biomedical research, ACTA PHARMACEUTICA is an essential resource for researchers, professionals, and students keen to stay abreast of the latest advancements and trends in these vital areas of study.

DARU-Journal of Pharmaceutical Sciences

Elevating the discourse in drug discovery and pharmacology.
Publisher: SPRINGER INT PUBL AGISSN: Frequency: 2 issues/year

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Pioneering insights in pharmacology and toxicology.
Publisher: FRONTIERS MEDIA SAISSN: Frequency: 1 issue/year

Welcome to the JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, a prestigious open access journal published by FRONTIERS MEDIA SA since 2008, dedicated to advancing research in the fields of pharmacy and pharmaceutical sciences. With its strong rooting in Canada, this journal has established itself within the academic community by consistently delivering high-quality studies and insights, as evidenced by its respectable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science categories for 2023, along with a notable 77th percentile ranking in Pharmaceutical Science on Scopus. Spanning over two decades of publication from 1998 to 2024, the journal focuses on critical research areas including pharmacology, toxicology, and drug development. By providing open access to its articles, the journal ensures that vital scientific information is readily available to researchers, professionals, and students alike, fostering collaboration and innovation within these essential disciplines. We invite you to explore the latest findings and contribute to the ongoing dialogue in pharmaceutical research through this essential platform.

FARMACIA

Championing Excellence in Pharmacology and Pharmaceutics.
Publisher: SOC STIINTE FARMACEUTICE ROMANIAISSN: 0014-8237Frequency: 6 issues/year

FARMACIA is a renowned academic journal published by the SOC STIINTE FARMACEUTICE ROMANIA, specializing in the field of pharmacology, toxicology, and pharmaceutics. With a rich history dating back to its initial publication years of 1945 to 1946, and ongoing contributions since 2008, the journal has established itself as a significant platform for disseminating cutting-edge research in the pharmaceutical sciences. Indexed in Scopus, it holds a commendable Q2 ranking in the Pharmacology, Toxicology and Pharmaceutics category, reflecting its importance in the field. The journal aims to foster knowledge sharing and innovation among researchers, professionals, and students alike, making it an essential resource for advancing pharmaceutical research. Although it does not currently offer Open Access, the content is accessible to a broad academic audience, ensuring valuable insights into current trends and discoveries in pharmacotherapy and drug development. For those seeking a deeper understanding of the evolving landscape of pharmaceutical sciences, FARMACIA provides a critical lens through which to explore and engage with the latest scientific advancements.

Journal of Reports in Pharmaceutical Sciences

Advancing Pharmaceutical Knowledge, One Report at a Time.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

SAUDI PHARMACEUTICAL JOURNAL

Connecting researchers and professionals for impactful pharmaceutical advancements.
Publisher: ELSEVIERISSN: 1319-0164Frequency: 8 issues/year

SAUDI PHARMACEUTICAL JOURNAL, published by Elsevier, stands as a pivotal platform for scholarly communication within the realm of pharmaceutical sciences and pharmacology. With a commendable Q2 ranking in both Pharmaceutical Science and Pharmacology for 2023, this journal reflects a strong commitment to advancing scientific understanding and innovation. Open Access since 2009, the journal ensures that cutting-edge research is readily accessible to researchers, professionals, and students around the globe, fostering collaboration and knowledge sharing. Based in the Netherlands, the journal covers a wide scope of topics, contributing to a cumulative understanding of drug development, therapeutic strategies, and pharmaceutical education. With a significant presence in Scopus rankings—#57 in Pharmaceutical Science and #116 in Pharmacology—SAUDI PHARMACEUTICAL JOURNAL is a trusted resource for high-quality research that shapes the future of pharmaceutical sciences.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Transforming Ideas into Effective Therapies
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-9045Frequency: 12 issues/year

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Exploring the frontiers of clinical pharmacy and therapeutics.
Publisher: WILEY-HINDAWIISSN: 0269-4727Frequency: 1 issue/year

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.